التفاصيل البيبلوغرافية
| العنوان: |
慢性粒细胞白血病患者BCR-ABL融合基因 P210表达对病程判断和预后评估的临床价值 (Chinese) |
| العنوان البديل: |
Clinical Value of BCR-ABL Fusion Gene P210 Expression of Patients with Chronic Myeloid Leukemia for Course Judgment and Prognosis Evaluation. (English) |
| المؤلفون: |
刘伟平, 官凡琪, 宋耀辉, 阮艳秋 |
| المصدر: |
Journal of Modern Laboratory Medicine; sep2019, Vol. 34 Issue 5, p12-15, 4p |
| مصطلحات موضوعية: |
CHRONIC myeloid leukemia, GENE fusion, LACTATE dehydrogenase, PROTEIN-tyrosine kinases, MYELOID leukemia, NEUTROPHILS, HYDROXYPROGESTERONE |
| الملخص (بالإنجليزية): |
Objective To investigate the clinical significance of the expression of BCR-ABL fusion gene P210 and peripheral blood images, lactate dehydrogenase (LDH), alpha-hydroxy butyrate dehydrogenase (HBDII), serum glucose (GLU),K and uric acid (UA) in the course judgment and prognosis evaluation of chronic myelogenous leukemia (CML). Methods Peripheral blood samples of 30 CML patients diagnosed in the First People’s Hospital of Zigong City from April 2017 to May 2018 were collected. The expression level of BCR-ABL fusion gene P210 in peripheral blood of 30 CML patients was determined by Real Time-PCR. Serum GLU, LDH and HBDLI dehydrogenase were determined simultaneously and combined with blood and bone marrow images of CML patients for comprehensive analysis. Results The positive expression rate of BCR-ABL fusion gene P210 in 30 CML patients was 93.3%,and the expression level of bcr-abl fusion gene P210 in different stages of leukemia was statistically significant (P<0.05). After 1 year of treatment with tyrosine kinase inhibitor (imatinib), the positive rate of bcr-abl P210 in 13 patients with CML decreased from 100% to 23.1% (3/13). There were statistically significant differences in the number of WBC,the number of neutrophils,and the ratio of neutrophils/lymphocytes between chronic myelogenous leukemia patients at different stages (P<0.05). Conclusion The expression of BCR-ABL P210 combined with WBC,hemoglobin,NEU/LYM,serum GLU and LDH is helpful for the course judgement and prognosis evaluation of CML. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
目的探讨BCR-ABL融合基因P210的表达与外周血象、cr羟丁酸脱氢酶（HBDH)、乳酸脱氢酶（LDH)和血糖 (GLU)对慢性粒细胞白血病（CML)的病程判断和预后评估中的临床意义。方法收集2017年4月~2018年5月在自贡 第一人民医院初诊确诊的慢性粒细胞白血病患者外周血标本；采用实时荧光定量PCR方法测定30例慢性粒细胞白血病 患者外周血BCR-ABL融合基因P210表达水平。同时测定GLU、LDH、HBDH、血清钾（K+ )和尿酸（UA)的含量，并结合 患者血象进行综合分析。结果 30例慢性粒细胞白血病患者BCR-ABL融合基因P210阳性表达率为93.3%，白血病不 同分期BCR-ABL融合基因P210表达量差异有统计学意义（P<0.05)。其中13例慢性期患者采用酪氨酸激酶抑制剂（伊 马替尼）治疗1年后，BCR-ABL P210阳性率由100%降低为23.1%(3/13)。不同时期慢性粒细胞白血病患者在白细胞数 量（WBC)、中性粒细胞/淋巴细胞比值（NEU/LYM)、血红蛋白（HGB)差异有统计学意义（P<0.05)。结论 BCR-ABL P210表达水平结合外周血WBC、HGB、NEU/LYM、GLU，LDH的检测，有助于慢性粒细胞白血病病程判断和预后评估。 [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Modern Laboratory Medicine is the property of Journal of Modern Laboratory Medicine Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
